Roundtable Discussion: Proving Long-Term Therapeutic Value Through Endpoint Selection & Clinical Trial Design
1:15 pm - Thursday 21st January 2027
Join breakout roundtables led by expert moderators to debate key questions, capture consensus and differing views, then reconvene as moderators share insights and spark wider audience debate.
- Discuss how the field should evolve beyond traditional visual acuity measures by identifying functional endpoints that better reflect real-world patient experience, including contrast sensitivity, low-light vision, and other measures of meaningful visual function
- Share experiences validating novel endpoints with regulatory agencies, exploring the evidence packages, study designs, and clinical data required to support acceptance of new outcome measures in future retinal trials
- Explore how predictive biomarkers, advanced imaging analytics, and emerging endpoint strategies can improve patient selection, accelerate development timelines, and generate stronger evidence for regulatory approval and long-term therapeutic value
- Debate which functional endpoints should be prioritised in future retinal studies, how they should be implemented within clinical trials, and what level of change represents a clinically meaningful benefit for patients